Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. - Test2 - elhamkhani - TriplyDB

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

http://www.wikidata.org/entity/Q38799468

about

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.Overexpression of stromal interaction molecule 1 may promote epithelial‑mesenchymal transition and indicate poor prognosis in gastric cancer Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.Niclosamide: Beyond an antihelminthic drug.Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC

P2860

Q30275354-53FC3433-CA72-49B6-B578-15769931E262 Q33828126-01B2D52B-A0BF-4A1B-BC3A-D5A8289A9E7D Q37725643-E8D67A59-7320-42A1-B643-A016EEEEC97F Q38598774-07EC553F-FB51-45A4-ABDB-BE6DBDCAD914 Q39227540-B269DB1F-96C5-4350-A653-2106971C4A86 Q47275485-4BDD3D0D-DDF4-4A47-8895-AA0AE5FF28CE Q58691275-5F1E4F56-8D25-4DBD-9312-DB7295BB9216 Q58708393-B0850B76-34D8-43AC-A630-F7BAEFF1AFEF

P2860

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

http://www.wikidata.org/entity/Q38799468

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Combined niclosamide with cisp ...... triple-negative breast cancer.

@en

type

label

Combined niclosamide with cisp ...... triple-negative breast cancer.

@en

prefLabel

Combined niclosamide with cisp ...... triple-negative breast cancer.

@en

P1433

Q38799468-9B57570C-07EB-4780-AFA4-E97757202509

P1476

Q38799468-6A987AC7-2FAA-4354-B54A-458F49DE8697

P2093

Q38799468-12318EF4-4C6E-4427-B2B7-76A1C44F9DAE

Q38799468-4EC8F86D-87C5-4E1A-9B18-53CA0219AD5E

Q38799468-BA0AC64B-896F-4D94-9515-C5B05B5F1A7E

Q38799468-D485A4A8-2D3D-488D-93B6-FB056B258231

Q38799468-F3FA0E3D-A5E4-473D-8F1A-64EF7C31420D

P2860

Q38799468-00CD7AF8-759B-40E0-8C22-609CAFCA05D2

Q38799468-0D6AE591-4034-4CCC-B28C-82356D241150

Q38799468-11A6A007-B6F2-4C8E-ACDF-29C780B8F5BF

Q38799468-2A40A688-8E19-4C96-AB3C-A513EDF2C496

Q38799468-2CC0B9BB-98F1-41DC-8D46-81451509267D

Q38799468-2F9ABE54-8254-443B-B09F-1C5AB88FC40A

Q38799468-324FA109-0CB7-454B-8BAD-A3B25E0F4119

Q38799468-32B6C35D-F2FC-4662-A42B-5836ED67096A

Q38799468-394FC854-5815-40AA-8FF1-7CDF4508DFF6

Q38799468-3A7D2CD9-E2A5-4162-B6E1-716F40E9E2DB

P2888

Q38799468-8303FAE3-6666-4FD0-B905-3E1681E6CAF0

P304

Q38799468-D0911B63-98E3-4059-A9AC-1B2DA2F50983

P31

Q38799468-270A02B3-FEAE-4339-B0AE-F32B55D2C93A

P356

Q38799468-4A845181-1E52-4367-A370-93F03B7BA49A

P433

Q38799468-C8F21546-3350-4741-B2D8-DA644BAFD3D3

P478

Q38799468-9D2D6DD3-3709-442B-ABC9-53E1E4813375

P577

Q38799468-0AD5C727-7C28-411E-887C-FAFC5B86A7CC

P6179

Q38799468-DDC7DEED-31C0-4A79-9BCE-E320AD7E6034

P698

Q38799468-54052AD9-BBBF-471B-860C-7474715D1AA0

P356

S13277-015-4650-1

P1433

P1476

Combined niclosamide with cisp ...... triple-negative breast cancer.

@en

P2093

Junjun Liu

http://www.w3.org/2001/XMLSchema#string

Kunwei Shen

http://www.w3.org/2001/XMLSchema#string

Mark Pegram

http://www.w3.org/2001/XMLSchema#string

Toby Ward

http://www.w3.org/2001/XMLSchema#string

Xiaosong Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

Identification of selective inhibitors of cancer stem cells by high-throughput screening

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway

Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells

Triple-Negative Breast Cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death.

P2888

s13277-015-4650-1

P304

9825-9835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-015-4650-1

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035821475

http://www.w3.org/2001/XMLSchema#string

P698

26810188

http://www.w3.org/2001/XMLSchema#string